Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours

Loading...
Thumbnail Image
Files
3793.pdf(912.06 KB)
Accepted version
Date
2017-09-13
Authors
Evans, James C.
Malhotra, Meenakshi
Sweeney, Katrina
Darcy, Raphael
Nelson, Colleen C.
Hollier, Brett G.
O'Driscoll, Caitríona M.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Research Projects
Organizational Units
Journal Issue
Abstract
The main barrier to the development of an effective RNA interference (RNAi) therapy is the lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the delivery of siRNA. In the present study, a folate-targeted amphiphilic cyclodextrin was formulated using DSPE-PEG5000-folate to target prostate cancer cells. The fusogenic peptide GALA was included in the formulation to aid in the endosomal release of siRNA. Targeted nanoparticles were less than 200 nm in size with a neutral surface charge. The complexes were able to bind siRNA and protect it from serum nucleases. Incubation with excess free folate resulted in a significant decrease in the uptake of targeted nanoparticles in LNCaP and PC3 cells, both of which have been reported to have differing pathways of folate uptake. There was a significant reduction in the therapeutic targets, ZEB1 and NRP1 at mRNA and protein level following treatment with targeted complexes. In preliminary functional assays using 3D spheroids, treatment of PC3 tumours with targeted complexes with ZEB1 and NRP1 siRNA resulted in more compact colonies relative to the untargeted controls and inhibited infiltration into the Matrigel™ layer.
Description
Keywords
RNAi , Cyclodextrin , GALA , siRNA delivery , Prostate cancer , Metastasis , Folate
Citation
Evans, J. C., Malhotra, M., Sweeney, K., Darcy, R., Nelson, C. C., Hollier, B. G. and O’Driscoll, C. M. (2017) 'Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours', International Journal of Pharmaceutics, 532(1), pp. 511-518. doi: 10.1016/j.ijpharm.2017.09.013